Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $112.87 million. The enterprise value is $43.39 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 62.02 million shares outstanding. The number of shares has increased by 23.94% in one year.
| Current Share Class | 62.02M |
| Shares Outstanding | 62.02M |
| Shares Change (YoY) | +23.94% |
| Shares Change (QoQ) | +1.42% |
| Owned by Insiders (%) | 6.28% |
| Owned by Institutions (%) | 21.84% |
| Float | 41.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.53 |
| Forward PS | n/a |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.65, with a Debt / Equity ratio of 0.22.
| Current Ratio | 5.65 |
| Quick Ratio | 5.20 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.80% and return on invested capital (ROIC) is -34.80%.
| Return on Equity (ROE) | -74.80% |
| Return on Assets (ROA) | -31.25% |
| Return on Invested Capital (ROIC) | -34.80% |
| Return on Capital Employed (ROCE) | -78.56% |
| Revenue Per Employee | $64,091 |
| Profits Per Employee | -$2.19M |
| Employee Count | 44 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.00% in the last 52 weeks. The beta is 1.15, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -50.00% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.30 |
| Relative Strength Index (RSI) | 69.41 |
| Average Volume (20 Days) | 811,131 |
Short Selling Information
The latest short interest is 4.33 million, so 6.99% of the outstanding shares have been sold short.
| Short Interest | 4.33M |
| Short Previous Month | 5.03M |
| Short % of Shares Out | 6.99% |
| Short % of Float | 10.52% |
| Short Ratio (days to cover) | 10.29 |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $2.82 million and -$96.29 million in losses. Loss per share was -$1.57.
| Revenue | 2.82M |
| Gross Profit | 2.82M |
| Operating Income | -82.91M |
| Pretax Income | -57.80M |
| Net Income | -96.29M |
| EBITDA | -80.54M |
| EBIT | -82.91M |
| Loss Per Share | -$1.57 |
Full Income StatementBalance Sheet
The company has $88.94 million in cash and $19.46 million in debt, giving a net cash position of $69.48 million or $1.12 per share.
| Cash & Cash Equivalents | 88.94M |
| Total Debt | 19.46M |
| Net Cash | 69.48M |
| Net Cash Per Share | $1.12 |
| Equity (Book Value) | 87.64M |
| Book Value Per Share | 1.41 |
| Working Capital | 82.28M |
Full Balance SheetCash Flow
| Operating Cash Flow | -73.75M |
| Capital Expenditures | n/a |
| Free Cash Flow | -73.75M |
| FCF Per Share | -$1.19 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,939.89% |
| Pretax Margin | -3,481.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.94% |
| Shareholder Yield | -23.94% |
| Earnings Yield | -85.30% |
| FCF Yield | -65.34% |
Analyst Forecast
The average price target for Pyxis Oncology is $7.75, which is 325.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.75 |
| Price Target Difference | 325.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 35.26% |
| EPS Growth Forecast (5Y) | -9.72% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of -3.73 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.73 |
| Piotroski F-Score | 2 |
